Loading stock…

Ultragenyx Pharmaceutical Inc. (RARE) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Ultragenyx Pharmaceutical Inc.

RAREMarket cap $1.46BPrice $14.9

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops treatments for rare genetic diseases so uncommon that most drugmakers won't touch them. Ultragenyx bets on ultra-rare disorders affecting just thousands of patients worldwide, turning tiny, overlooked markets into a growing portfolio of approved therapies and pipeline bets.

In Bastion Portfolios?

52W Return-54%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+23%9

Revenue Forecast

Rev CAGR (1y)+13%7

Rev CAGR (3y)+20%9

Rev CAGR (5y)+18%9

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+30%5

Quality

Margins

EBIT Margin-69%1

Net Income Margin-82%1

Free Cash Flow Margin-68%1

Debt

Net Debt/EBITDAna–

Efficiency

ROE-775%1

ROA-46%1

Earnings Stabilityna–

GEAR+VERY WEAK7

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)136

P/BVna–

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-33.4%1

Dividend Yieldna–

Momentum

Short term

1 month return+0%8

3 month return-57%1

YTD return-35%1

Mid term

Price vs 52wHigh37%1

1 year return-52%1

Long term

3 year return-58%1

5 year return-82%1

Risk Shield

Price Risk

Beta1.42

Volatility96%1

Free Cash Flow

Free Cash Flow Margin-68%1

Free Cash Flow Yield-33.4%1

Quality

ROCE-52%1

Earnings Stabilityna–

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

RAREUltragenyx Pharmaceutical

Revenue FY25$560M

GROWTH RATING↗

STRONG76 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+23%9

Revenue, next 1Y+13%7

Revenue, next 3Y, CAGR+20%9

Revenue, next 5Y, CAGR+18%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28E0%5

GROWTH ASSESSMENT

STRENGTHS

It out-grows 76% of companies worldwide.

Revenue grew 23%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 20%/yr over the next 3 years, ahead of most of the market.8/10

The runway holds up: revenue is set to grow 18%/yr over five years.9/10

WATCH

Revenue grew 23%/yr over the last 3 years; forecasts see it cooling to 20%/yr.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that is slowing. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK5 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+0%8

3-month return-57%1

YTD return-35%1

MID & LONG-TERM▾SCORE

% of 52-week high37%1

1-year return-52%1

3-year return-58%1

5-year return-82%1

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+0%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-58% over three years and -82% over five), behind 90% of the market.

It's down 52% over the past year, now 63% below its 52-week high. That is lagging the market.

The stock is underperforming over three months (-57%) and so far this year (-35%).

BOTTOM LINE

Weak Tape

Returns across short and long horizons rank poorly versus the market. Momentum offers no support here; the case has to come from other factors. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Ultragenyx Pharmaceutical Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

RAREUltragenyx Pharmaceutical

Revenue FY25$560M

GROWTH RATING↗

STRONG76 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+23%9

Revenue, next 1Y+13%7

Revenue, next 3Y, CAGR+20%9

Revenue, next 5Y, CAGR+18%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28E0%5

GROWTH ASSESSMENT

STRENGTHS

It out-grows 76% of companies worldwide.

Revenue grew 23%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 20%/yr over the next 3 years, ahead of most of the market.8/10

The runway holds up: revenue is set to grow 18%/yr over five years.9/10

WATCH

Revenue grew 23%/yr over the last 3 years; forecasts see it cooling to 20%/yr.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that is slowing. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK5 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+0%8

3-month return-57%1

YTD return-35%1

MID & LONG-TERM▾SCORE

% of 52-week high37%1

1-year return-52%1

3-year return-58%1

5-year return-82%1

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+0%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-58% over three years and -82% over five), behind 90% of the market.

It's down 52% over the past year, now 63% below its 52-week high. That is lagging the market.

The stock is underperforming over three months (-57%) and so far this year (-35%).

BOTTOM LINE

Weak Tape

Returns across short and long horizons rank poorly versus the market. Momentum offers no support here; the case has to come from other factors. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Ultragenyx Pharmaceutical Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community